Provided by Tiger Trade Technology Pte. Ltd.

Tscan Therapeutics, Inc.

0.3167
-0.0134-4.06%
Volume:455.47K
Turnover:149.15K
Market Cap:21.47M
PE:-0.35
High:0.3498
Open:0.3202
Low:0.3115
Close:0.3301
52wk High:2.57
52wk Low:0.3115
Shares:67.78M
Float Shares:57.82M
Volume Ratio:0.28
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9000
EPS(LYR):-2.2805
ROE:-95.80%
ROA:-31.53%
PB:0.31
PE(LYR):-0.14

Loading ...

Analysts Conflicted on These Healthcare Names: Alpha Cognition Inc (ACOG) and TScan Therapeutics (TCRX)

TIPRANKS
·
Aug 17

Atea Pharmaceuticals Q2 Loss Narrows as HCV Trial Expenses Decline

Reuters
·
Aug 13

Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Eli Lilly & Co (LLY)

TIPRANKS
·
Aug 12

TScan Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 12

TScan Therapeutics Q2 Net Income USD -30.359 Million

THOMSON REUTERS
·
Aug 12

Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets

Dow Jones
·
Aug 11

TScan Therapeutics Inc Expected to Post a Loss of 21 Cents a Share - Earnings Preview

Reuters
·
Aug 07

TScan Therapeutics Announces First Patient Dosed in Phase 3 Alloha-2™, a Pivotal Trial Evaluating Tsc-101 in Patients with Heme Malignancies

THOMSON REUTERS
·
Jul 29

Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Relmada Therapeutics (RLMD)

TIPRANKS
·
Jun 23

TScan publishes ALLOHA Cohort C Phase 1 presentation for TSC-101 TCR-T therapy in post-transplant AML, ALL and MDS

Reuters
·
Jun 22

TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment

MT Newswires Live
·
Jun 22

TScan reports Phase 1 Cohort C data showing 11 of 14 patients reach complete donor chimerism after TSC-101 infusion

Reuters
·
Jun 22

TScan Therapeutics - on Track to Enroll First Patient in Phase 3 Alloha-2 Study of Tsc-101 This Month

THOMSON REUTERS
·
Jun 22

TScan Therapeutics Announces Positive Initial Data From Cohort C of Ongoing Alloha™ Phase 1 Study Evaluating Tsc-101 in Patients With Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

THOMSON REUTERS
·
Jun 22

TScan Therapeutics - Tsc-101 Continues to Be Well-Tolerated

THOMSON REUTERS
·
Jun 22

TScan Therapeutics teams with Cellares to evaluate automated manufacturing of TSC-101 TCR-T therapy

Reuters
·
Jun 03

TScan Therapeutics - Expects to Begin Pivotal Tsc-101 Trial in Q2 2026

THOMSON REUTERS
·
Jun 03

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of Tsc-101 for Patients With Hematologic Malignancies

THOMSON REUTERS
·
Jun 03

TScan Therapeutics - Agreement Adds Tcr-T Cell Therapies to Cellares Automated Portfolio

THOMSON REUTERS
·
Jun 03